FDA To Address Industry Questions In Transparency Effort
This article was originally published in The Tan Sheet
Executive Summary
FDA has expanded its transparency initiative to cover an unanticipated area - explaining how the agency works to the industries it regulates
You may also be interested in...
FDA Transparency Has No Clear Path To Releasing Documents - Woodcock
The possible release of FDA's voluminous documents is one of the more challenging aspects - both in policies and resources - of the agency's effort to make its operations and decisions more open to the public, FDA's Janet Woodcock says
"Complete Response" Transparency Could Spur Better Applications - Jenkins
Office of New Drugs Director John Jenkins sees a possible side benefit for FDA of more efficient drug approval processes should the agency's transparency initiative lead to the public release of "complete response" letters
Information Disclosure Issues Challenge FDA Transparency Task Force
FDA questions whether to disclose information on product applications that a company abandons before approval or in some cases on applications in which review is still pending